Evans Syndrome at Childhood-Onset Systemic Lupus Erythematosus Diagnosis: A Large Multicenter Study

Background Evans syndrome (ES) in childhood‐onset systemic lupus erythematosus (cSLE) patients has been rarely reported and limited to small populations. Procedures A retrospective multicenter cohort study (Brazilian cSLE group) was performed in 10 Pediatric Rheumatology services including 850 patie...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer Vol. 63; no. 7; pp. 1238 - 1243
Main Authors: Lube, Gabriella E., Ferriani, Mariana Paes Leme, Campos, Lucia Maria Arruda, Terreri, Maria Teresa, Bonfá, Eloisa, Magalhães, Claudia Saad, Aikawa, Nadia Emi, Piotto, Daniela Petry, Peracchi, Octavio Augusto Bedin, dos Santos, Maria Carolina, Appenzeller, Simone, Ferriani, Virginia Paes Leme, Pereira, Rosa Maria Rodrigues, Silva, Clovis Artur
Format: Journal Article
Language:English
Published: United States Blackwell Publishing Ltd 01-07-2016
Wiley Subscription Services, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Evans syndrome (ES) in childhood‐onset systemic lupus erythematosus (cSLE) patients has been rarely reported and limited to small populations. Procedures A retrospective multicenter cohort study (Brazilian cSLE group) was performed in 10 Pediatric Rheumatology services including 850 patients with cSLE. ES was assessed at disease diagnosis and defined by the combination of immune thrombocytopenia and autoimmune hemolytic anemia. Results ES was observed in 11 of 850 (1.3%) cSLE patients. The majority of them had hemorrhagic manifestations (91%) and active disease (82%). All patients with ES were hospitalized and none died. Comparisons of cSLE patients with and without ES at diagnosis revealed similar frequencies of female gender, multiorgan involvement, autoantibodies profile, and low complement (P > 0.05). Patients with ES had a lower frequency of malar rash (9% vs. 53%, P = 0.003) and musculoskeletal involvement (18% vs. 69%, P = 0.001) than those without this complication. The frequencies of intravenous methylprednisolone (82% vs. 43%, P = 0.013) and intravenous immunoglobulin use (64% vs. 3%, P < 0.0001) were significantly higher in the ES group, with similar current prednisone dose between groups (1.1 [0.76–1.5] vs. 1.0 mg/kg/day [0–30], P = 0.195). Conclusions Our large multicenter study identified ES as a rare and severe initial manifestation of active cSLE with good outcome. Diagnosis is challenging due to the lack of typical signs and symptoms of lupus and the requirement to exclude infection and primary immunodeficiency.
Bibliography:istex:37ADEC178B4224AAE764B579E017452BCC74F3A1
Conselho Nacional de Desenvolvimento Científico e Tecnológico - No. 303422/2015-7
ark:/67375/WNG-M0HWKR9C-0
ArticleID:PBC25976
Grant sponsor: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq 303422/2015‐7); Grant sponsor: Federico Foundation; Grant sponsor: Núcleo de Apoio à Pesquisa “Saúde da Criança e do Adolescente” da USP (NAP‐CriAd).
Conflict of interest: Nothing to declare.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.25976